Momenta Pharmaceuticals (NASDAQ:MNTA) reported first-quarter earnings on Tuesday, but given the relatively small sales, it was an update on the potential FDA approval of higher-strength Glatopa and pipeline plans that should most interest investors.
What happened with Momenta Pharmaceuticals this quarter?